Skip to Content
Merck

Adenine phosphoribosyltransferase deficiency.

Clinical journal of the American Society of Nephrology : CJASN (2012-06-16)
Guillaume Bollée, Jérôme Harambat, Albert Bensman, Bertrand Knebelmann, Michel Daudon, Irène Ceballos-Picot
ABSTRACT

Complete adenine phosphoribosyltransferase (APRT) deficiency is a rare inherited metabolic disorder that leads to the formation and hyperexcretion of 2,8-dihydroxyadenine (DHA) into urine. The low solubility of DHA results in precipitation of this compound and the formation of urinary crystals and stones. The disease can present as recurrent urolithiasis or nephropathy secondary to crystal precipitation into renal parenchyma (DHA nephropathy). The diagnostic tools available-including stone analysis, crystalluria, and APRT activity measurement-make the diagnosis easy to confirm when APRT deficiency is suspected. However, the disease can present at any age, and the variability of symptoms can present a diagnostic challenge to many physicians. The early recognition and treatment of APRT deficiency are of crucial importance for preventing irreversible loss of renal function, which still occurs in a non-negligible proportion of cases. This review summarizes the genetic and metabolic mechanisms underlying stone formation and renal disease, along with the diagnosis and management of APRT deficiency.

MATERIALS
Product Number
Brand
Product Description

Sigma-Aldrich
Adenine, Vetec, reagent grade, ≥99%
Sigma-Aldrich
Adenine, BioReagent, suitable for cell culture
Sigma-Aldrich
Adenine, ≥99%
Sigma-Aldrich
Adenine, BioReagent, suitable for plant cell culture, ≥99%
Supelco
Adenine, Pharmaceutical Secondary Standard; Certified Reference Material
Adenine, European Pharmacopoeia (EP) Reference Standard